Felipe Fornias Sperandio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felipe Fornias Sperandio has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- João Adolfo Costa Hanemann
Federal University of Alfenas
3 shared publications - Alessandro Antônio Costa Pereira
Federal University of Alfenas
2 shared publications - Carine Ervolino de Oliveira
Universidade Federal de Alfenas
2 shared publications - Marta Miyazawa
Faculdade de Odontologia, Universidade Federal de Alfenas, Alfenas 37130-001, MG, Brazil
2 shared publications - Aline Corrêa Abrahão
Department of Oral Diagnosis and Pathology, School of Dentistry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
1 shared publication - Bianca Caroline Figueiredo Bianco
Department of Bioscience, Faculdade de Odontologia de Piracicaba, Universidade de Campinas (FOP/UNICAMP), Piracicaba, Brazil
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Universidade Estadual de Campinas in Brazilian Journal of Oral Sciences
- Vol. 25, e266776
Impact of the COVID-19 pandemic on oral lesions diagnosed through biopsy in pediatric patients
Aim: To compare the patterns of diagnosis for oral lesions and the number of biopsies performed in children aged 0 to 12 years before and during the COVID-19 pandemic in a Brazilian Oral Pathology Service. Methods: In this retrospective cross-sectional study, data were collected from patient records and biopsy forms, including demographic information, clinical diagnosis, lesion duration, localization, and symptomatology of oral lesions. Data were categorized into three periods: prepandemic, first pandemic, and second pandemic. Results: A total of 99 cases (43 boys and 56 girls) were included, with the highest mean age recorded during the first and second pandemic periods. Salivary gland pathology (n = 28, 28.1%), reactive lesions (n = 20, 20.2%), and developmental and inflammatory cysts (n = 18, 18.2%) were the most frequent diagnoses. Lesions presenting as bullae and vesicles were significantly associated with a duration of 1 to 6 months. A significant decrease in the number of oral biopsies performed was observed across the prepandemic (n = 46, 46.5%), first pandemic (n = 28, 28.3%), and second pandemic (n = 25, 25.3%) periods. Conclusions: Despite the disruption of healthcare services caused by the COVID-19 pandemic, there was no significant increase in the frequency of oral lesions in pediatric patients. However, the mean age of the patients increased during the pandemic periods, suggesting potential delays in diagnosis. Additionally, the total number of oral biopsies in children substantially decreased.
- 21 January 2026
- Published by Universidade Estadual de Campinas in Brazilian Journal of Oral Sciences
- Vol. 25, e266776
Open AccessImpact of the COVID-19 pandemic on oral lesions diagnosed through biopsy in pediatric patients
Aim: To compare the patterns of diagnosis for oral lesions and the number of biopsies performed in children aged 0 to 12 years before and during the COVID-19 pandemic in a Brazilian Oral Pathology Service. Methods: In this retrospective cross-sectional study, data were collected from patient records and biopsy forms, including demographic information, clinical diagnosis, lesion duration, localization, and symptomatology of oral lesions. Data were categorized into three periods: prepandemic, first pandemic, and second pandemic. Results: A total of 99 cases (43 boys and 56 girls) were included, with the highest mean age recorded during the first and second pandemic periods. Salivary gland pathology (n = 28, 28.1%), reactive lesions (n = 20, 20.2%), and developmental and inflammatory cysts (n = 18, 18.2%) were the most frequent diagnoses. Lesions presenting as bullae and vesicles were significantly associated with a duration of 1 to 6 months. A significant decrease in the number of oral biopsies performed was observed across the prepandemic (n = 46, 46.5%), first pandemic (n = 28, 28.3%), and second pandemic (n = 25, 25.3%) periods. Conclusions: Despite the disruption of healthcare services caused by the COVID-19 pandemic, there was no significant increase in the frequency of oral lesions in pediatric patients. However, the mean age of the patients increased during the pandemic periods, suggesting potential delays in diagnosis. Additionally, the total number of oral biopsies in children substantially decreased.
- 28 February 2025
- Published by Wiley in Gerodontology
- Vol. 42 (1) , 119-123
Medication‐related osteonecrosis of the jaw in an older patient with multiple myeloma
Objective: This article reports a case of medication‐related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM). Background: Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication‐related osteonecrosis of the jaw (MRONJ). Materials and Methods: A 67‐year‐old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ. Results: MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow‐up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence. Conclusion: Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.
- 28 February 2025
- Published by Wiley in Gerodontology
- Vol. 42 (1) , 119-123
Medication‐related osteonecrosis of the jaw in an older patient with multiple myeloma
Objective: This article reports a case of medication‐related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM). Background: Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication‐related osteonecrosis of the jaw (MRONJ). Materials and Methods: A 67‐year‐old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ. Results: MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow‐up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence. Conclusion: Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.
- Open Access
- 23 March 2022
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 68 (2)
Development and Evolution of a Diagnostic and Oral Pathology Service in a Southeast Brazilian State
Introduction: Oral squamous cell carcinoma (OSCC) is one of the most frequent cancers whose main causes are preventable because oral cavity is easily accessible for examination. OSCC involves many steps from the diagnosis until treatment which can result in late diagnosis and worst prognosis. Objective: Development and evolution of a Stomatology and Oral Pathology Service at the Federal University of Alfenas addressing early diagnosis and management of oral lesions. Method: Retrospective study developed with the files from 1998 to 2019. Data from all the cases diagnosed as oral malignancies were collected and the demographical, clinical, and microscope diagnosis were included. Results: 270 (84.64%) OSCC were found among 8,952 histopathological diagnoses. The patients age ranged from 24 to 94 years (mean 59.7±13.1 years), and more frequent in the sixth (32.3%) and seventh (26%) decades of life. Men were 2.5 times more affected than women. Most of patients were Caucasian (74.8%), and users of tobacco and alcohol. Over the years, there was an increase in the number of cases diagnosed and expansion of the area covered by the Service. Conclusion: The Dental Clinic (Stomatology) and Oral Pathology Laboratory has been playing an important role for the establishment and improvement of the healthcare system to the local population, mainly in rural areas.
- 23 March 2022
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 68 (2)
Open AccessDevelopment and Evolution of a Diagnostic and Oral Pathology Service in a Southeast Brazilian State
Introduction: Oral squamous cell carcinoma (OSCC) is one of the most frequent cancers whose main causes are preventable because oral cavity is easily accessible for examination. OSCC involves many steps from the diagnosis until treatment which can result in late diagnosis and worst prognosis. Objective: Development and evolution of a Stomatology and Oral Pathology Service at the Federal University of Alfenas addressing early diagnosis and management of oral lesions. Method: Retrospective study developed with the files from 1998 to 2019. Data from all the cases diagnosed as oral malignancies were collected and the demographical, clinical, and microscope diagnosis were included. Results: 270 (84.64%) OSCC were found among 8,952 histopathological diagnoses. The patients age ranged from 24 to 94 years (mean 59.7±13.1 years), and more frequent in the sixth (32.3%) and seventh (26%) decades of life. Men were 2.5 times more affected than women. Most of patients were Caucasian (74.8%), and users of tobacco and alcohol. Over the years, there was an increase in the number of cases diagnosed and expansion of the area covered by the Service. Conclusion: The Dental Clinic (Stomatology) and Oral Pathology Laboratory has been playing an important role for the establishment and improvement of the healthcare system to the local population, mainly in rural areas.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 28, e20190067
New WHO odontogenic tumor classification: impact on prevalence in a population
This study approaches the history of reclassifications and redefinitions around the odontogenic keratocyst (OK), as proposed by the World Health Organization (WHO), and aims to understand the impact of those changes on the prevalence and epidemiology of odontogenic tumors (OTs). Cases of OTs diagnosed in an Oral Pathology service between January 1996 and December 2016 were reviewed. Demographic data of patients such as age, gender and site of lesions were retrieved from their respective records. Within the studied period, 7,805 microscopic reports were elaborated and 200 (2.56%) of these were diagnosed as OTs. Out of these 200, between 1996 and 2005, prior to the 2005 WHO classification, there were 41 (20.5%) OTs cases, being odontoma the most frequent (23; 56.09%), followed by ameloblastoma (8; 19.51%) and myxoma (03; 7.31%). Between 2006 and 2016, after the previous 2005 WHO classification there were 159 (79.5%) OTs, being odontogenic keratocystic tumor (KCOT) the most frequent (68; 42.76%), followed by odontoma (39; 24.52%) and ameloblastoma (21; 13.20%). As of today, the most recent WHO classification to be followed brings KCOT back to the cyst category, which will impact on the prevalence and epidemiology of OTs; thus, this study was able to identify a considerable increase (287.80%) in the prevalence of OTs when the 2005 WHO classification was utilized. Despite being an important academic exercise, classifying odontogenic lesions and determining whether to place the odontogenic keratocyst in a cyst or tumor category is crucial to establish the correct diagnosis and treatment to follow, whether by oral medicine or oral surgery specialist, or by the general practitioner.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 28, e20190067
Open AccessNew WHO odontogenic tumor classification: impact on prevalence in a population
This study approaches the history of reclassifications and redefinitions around the odontogenic keratocyst (OK), as proposed by the World Health Organization (WHO), and aims to understand the impact of those changes on the prevalence and epidemiology of odontogenic tumors (OTs). Cases of OTs diagnosed in an Oral Pathology service between January 1996 and December 2016 were reviewed. Demographic data of patients such as age, gender and site of lesions were retrieved from their respective records. Within the studied period, 7,805 microscopic reports were elaborated and 200 (2.56%) of these were diagnosed as OTs. Out of these 200, between 1996 and 2005, prior to the 2005 WHO classification, there were 41 (20.5%) OTs cases, being odontoma the most frequent (23; 56.09%), followed by ameloblastoma (8; 19.51%) and myxoma (03; 7.31%). Between 2006 and 2016, after the previous 2005 WHO classification there were 159 (79.5%) OTs, being odontogenic keratocystic tumor (KCOT) the most frequent (68; 42.76%), followed by odontoma (39; 24.52%) and ameloblastoma (21; 13.20%). As of today, the most recent WHO classification to be followed brings KCOT back to the cyst category, which will impact on the prevalence and epidemiology of OTs; thus, this study was able to identify a considerable increase (287.80%) in the prevalence of OTs when the 2005 WHO classification was utilized. Despite being an important academic exercise, classifying odontogenic lesions and determining whether to place the odontogenic keratocyst in a cyst or tumor category is crucial to establish the correct diagnosis and treatment to follow, whether by oral medicine or oral surgery specialist, or by the general practitioner.
- 16 May 2013
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 42 (10) , 793-798
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma
Background: Celecoxib, a non‐steroidal anti‐inflammatory drug that selectively inhibits cyclooxygenase‐2 (COX‐2), has shown an important anticarcinogenic effect for the treatment of squamous cell carcinoma. The use of COX‐2 inhibitors has effectively inhibited the growth of Head and Neck Squamous Cell Carcinoma (HNSCC) cell lines, while a recent phase 1 trial demonstrated good response rate of cancer cells to this drug with minimal toxicity. Possible targets of celecoxib include proteins involved in cell proliferation and apoptosis control. Additionally, celecoxib antitumoral activity has been linked with a COX‐2‐independent event.Methods: To better understand which cellular mechanisms are targeted by celecoxib, its effects upon the Akt signaling pathway using two different HNSCC cell lines were analyzed through cell viability assay, immunofluorescence, and Western blotting.Results: The results showed decreased levels of Cyclin D1 and pAkt protein expression in vitro. The number of viable cells was also diminished after celecoxib treatment.Conclusion: As Akt pathway seems to be a valuable target for the HNSCC therapy, the results presented herein confirm that celecoxib can be considered as an alternative adjuvant drug for HNSCC treatment.
- 16 May 2013
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 42 (10) , 793-798
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma
Background: Celecoxib, a non‐steroidal anti‐inflammatory drug that selectively inhibits cyclooxygenase‐2 (COX‐2), has shown an important anticarcinogenic effect for the treatment of squamous cell carcinoma. The use of COX‐2 inhibitors has effectively inhibited the growth of Head and Neck Squamous Cell Carcinoma (HNSCC) cell lines, while a recent phase 1 trial demonstrated good response rate of cancer cells to this drug with minimal toxicity. Possible targets of celecoxib include proteins involved in cell proliferation and apoptosis control. Additionally, celecoxib antitumoral activity has been linked with a COX‐2‐independent event.Methods: To better understand which cellular mechanisms are targeted by celecoxib, its effects upon the Akt signaling pathway using two different HNSCC cell lines were analyzed through cell viability assay, immunofluorescence, and Western blotting.Results: The results showed decreased levels of Cyclin D1 and pAkt protein expression in vitro. The number of viable cells was also diminished after celecoxib treatment.Conclusion: As Akt pathway seems to be a valuable target for the HNSCC therapy, the results presented herein confirm that celecoxib can be considered as an alternative adjuvant drug for HNSCC treatment.